ERBB2 and breast carcinoma: It is proposed that in cases of breast cancer with trastuzumab resistance, the addition of a TKI aids in overcoming resistance due to the shedding of the extracellular domain of HER2, which typically results in less effective binding of the unconjugated antibody [74].